Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
November 01, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Mendus AB: Mendus säkrar tillverkning av DCP-001 för potentiellt registreringsgrundande studier och kommersialisering
October 18, 2022 02:00 ET
|
Mendus AB
AVTALET LIGGER I LINJE MED KLINISK UTVECKLINGSSTRATEGI FÖR DCP-001 Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som adresserar tumöråterfall, har idag...
Mendus AB: Mendus secures manufacturing partner for establishing potential pivotal trial-stage and commercial production of DCP-001
October 18, 2022 02:00 ET
|
Mendus AB
TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today...
Bone Therapeutics et Link Health signent un accord non-contractuel pour les droits mondiaux d’ALLOB
November 29, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION REGLEMENTEE Link Health recevra les droits mondiaux pour le développement, la fabrication et la commercialisation d'ALLOB. Bone Therapeutics sera éligible dès la...
Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB
November 29, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION Link Health to be granted global rights for development, manufacturing and commercialization of ALLOB Bone Therapeutics to receive R&D cost reimbursement,...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
November 02, 2021 16:01 ET
|
MacroGenics, Inc.
Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP...
Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries
September 09, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
June 16, 2021 07:30 ET
|
MacroGenics, Inc.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
Bone Therapeutics et Rigenerand signent un partenariat pour le développement d’un processus de thérapie cellulaire
January 14, 2021 01:00 ET
|
Bone Therapeutics SA
Gosselies, Belgique et Modène, Italie, le 14 janvier 2021, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de...
Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
January 14, 2021 01:00 ET
|
Bone Therapeutics SA
Gosselies, Belgium and Modena, Italy, 14 January 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and...